Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared on LinkedIn about a recent paper by Patrick Neven et al. published on Nature:
“Great review of the vepdegestrant data presented at ASCO25 as well as the current status of the field post-1L CD4/6 inhibitor.”
Title: PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations
Authors: Patrick Neven and Sileny N. Han
